Close
Nordic 9Nordic 9

CTI Life Sciences (investor - Venture Capital)

Canada ctisciences.com
See something wrong or missing? Let us know
Offices:Montreal

CTI Life Sciences Fund is a Canadian investment company that makes venture capital investments in high quality emerging life science companies at the pre-clinical and clinical development stages.

Average round investment:46.73M USD
Average number per year:1.7
Distribution: 2024 (2)2023 (1)2022 (2)
Portfolio companies: United Kingdom EpitopeaSpain Ability PharmaFrance Amolyt Pharma See the entire list
Mostly invests in: United Kingdom United Kingdom (2) Health services (5)
See the entire list

Showing 3 of 5 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to CTI Life Sciences

Name Criteria
United Kingdom 4BIO Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland SkyViews Life Science
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States Compound VC
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France, Spain
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States Data Collective (DCVC)
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
Germany 415 Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Longitude Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Switzerland MTIP AG
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France, Spain
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Austria Hil-Invent GmbH
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
France AdBio partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France, Spain
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Germany PS Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Top